NEW YORK (PRWEB)
February 16, 2022

The Healthcare Technology Report is pleased to announce The Top 25 Biotech CEOs of 2022. Over the past year, these leading biotechnology executives and their organizations have demonstrated ingenuity, skill, and perseverance in solving tremendous challenges. The specialties of this year’s CEOs and their companies run the gamut from gene therapy to vaccine development, cancer treatment, proteomics, mRNA-based therapeutics, and much more. Many of the awardees have also found success in raising significant amounts of funding for their companies, which enables them to continue to have positive impact on the biotechnology field for years to come.

Through their tireless work, these CEOs have succeeded in advancing research and bringing breakthrough drugs and treatments to market. For instance, Franz-Werner Haas and his company CureVac are currently focused on the development of its second-generation mRNA COVID-19 vaccine candidate, CV2CoV, in collaboration with GSK. Meanwhile, Dr. Roy Smythe and SomaLogic have leveraged artificial intelligence and machine learning to develop its first-in-class, high-plex proteomics SomaSignal™ tests, which are redefining diagnostics in precision medicine. And the diverse pipeline of RNA vaccines and therapeutics of Joseph Payne and Arcturus Therapeutics includes programs pursuing COVID-19 and flu vaccines, rare diseases, Hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and glycogen storage disease type III.

One achievement all of our honorees share is the notable contributions they have made towards advancing the biotechnology industry. From hundreds of nominees, these executives stood out for their unflagging commitment to improving lives through the advancement of medicine. Please join us in recognizing the accomplishments of The Top 25 Biotech CEOs of 2022.

Emma Walmsley (GlaxoSmithKline), Charles Brown (LifeLabs Medical Laboratory), Dr. Emil Kakkis (Ultragenyx Pharmaceutical), Franz-Werner Haas (CureVac), Dr. Roy Smythe (SomaLogic), Paul Dabrowski (Synthego Corporation), Joseph Payne (Arcturus Therapeutics), Scott Hutton (Biodesix), Gaurav Shah (Rocket Pharmaceuticals), Norman Sharples (COPAN Diagnostics), Dr. Oguzhan Atay (BillionToOne), Thomas Ybert (DNA Script), Dr. Scott Braunstein (Marinus Pharmaceuticals), Sarah Boyce (Avidity Biosciences), Todd Zavodnick (Dermavent Sciences), Alexander Lorestani (Geltor), John Vitalie (Aizon), Dr. Bobak Azamian (Tarsus Pharmaceuticals), Dr. Joanne Smith-Farrell (Be Biopharma), Andrew Barnell (Geneoscopy), Dwight Egan (Co-Diagnostics), Charles Fisher (Unlearn.AI), James Peyer (Cambrian Biopharma), Alex Martin (Palladio Biosciences), Scott Megill (Coriell Life Sciences), Dr. Christopher Thanos (Actym Therapeutics), Thurein Htoo (Qlaris Bio).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers and media professionals highly knowledgeable on healthcare technology and the various companies, executives and investors that make up the sector.

Share article on social media or email: